next generation semaglutide Next-Generation Anti-Obesity Medicines Semaglutide drives weight loss through

Kidney and heart failure outcomes associated with SGLT2 inhibitor use

GLP-1 receptor agonists, as established in earlier sections, independently produce average weight reductions of 15 to 22% of total body weight in the STEP and SURMOUNT trial programs [8,9]

doi: 10.1016/j.phrs.2015.10.008 22 MahapatraMKKaruppasamyMSahooBM

And if they end up contributing more than they're allowed to as a result, then they'll be forced to withdraw the excess contribution (and any growth attributable to it) or else face a 6% excise tax per year on the excess contribution until it is eventually withdrawn

* Daro Pescador es editor y director de la revista Quo y autor del libro Tu mejor yo publicado por Oberon